Response to ASX Price Query
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Amplia Therapeutics Ltd. has responded to a price query from the ASX regarding recent trading activity in its securities, confirming it is not aware of any undisclosed information that could explain the trading changes. The company stated it is complying with the ASX Listing Rules and that its responses were authorized by the Managing Director.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Amplia Therapeutics Ltd. on 6ix
Earlier from Amplia Therapeutics
- Amplia signs Collaboration and Supply Agreement with Lilly
- Scientific Paper Detailing Preclinical Studies of Narmafotinib in Pancreatic Cancer Now Online
- Amplia Announces Publication of New FAK Inhibitor Patent Application
- Amplia Announces Appointment of Brett Carter to Board
- Amplia Announces Changes to Board’s Leadership Roles
Follow Amplia Therapeutics into a list and get an email when it puts out news.
Follow Amplia Therapeutics